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This month’s issue of the Journal contains a somewhat
unusual article and two accompanying editorials [1–3].
The authors of the article are members of the steering
committee of an ongoing Eli-Lilly trial on activated
protein C for persistent septic shock. They describe a
number of steps that have been adopted in order to ensure
transparency in disclosing financial conflicts, facilitate
comprehension and interpretation of results, minimize
possible risks, and maximize eventual benefits for
patients. This approach constitutes a new model of aca-
demia-industry collaboration.
The importance of the initiative is that the study will or
will not confirm the results obtained in a pivotal trial [4]
that has evoked bitter controversy over recent years. Such
debate is founded on issues of inconsistency in results,
possible risks of treatment, and lack of reproducibility of
data [5–12]. Furthermore, Eli-Lilly was criticized for
conducting what has been viewed as a carefully targeted
advertising campaign [13, 14].
One may reasonably argue that by publishing this
article, we in some way promote this new Eli-Lilly-
sponsored trial. One may also point out that this could be
a subtle way to help recruit subjects into the trial. And it
may also appear that Intensive Care Medicine, the official
journal of the European Society of Intensive Care Medi-
cine, hereby endorses this trial.
However, this is not the case. The Journal decided to
publish the article and the two editorials for a number of
reasons. First of all, the authors clearly state their finan-
cial conflicts with the sponsor and outline their
relationship with Eli-Lilly in full. Second, our aim is to
provide the public and also physicians enrolling subjects
into this trial with further scientific background on acti-
vated protein C. Third, we wish to emphasize that
publication of this article and the investigation protocol
(as an electronic supplementary material file) in no way
implies an imprimatur by Intensive Care Medicine.
Fourth, although there is still far to go before we reach an
ideal scenario of industry–researcher collaboration, we
welcome this unprecedented step forward. And lastly, we
believe this trial is fundamental in order to comply with
one of the major requirements of medical science:
reproducibility.
The novelty here is the full disclosure of the process by
which this study was designed, and a description of how it
will be conducted, analyzed and reported. We thank the
authors, the reviewers and the editorialists for their fair
and honest commitment to maintaining the integrity of the
editorial process. We hope all this will facilitate rigorous
interpretation of the data and will contribute to the dis-
semination of scientific information that can help
clinicians, our readers, to serve better their patients.
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